

## CONTENTS

TITLE	PAGE NO.
<b>CHAPTER 1: INTRODUCTION</b>	1-28
1.1 Classification of impurities	2
1.2 Identification and Qualification thresholds of impurities and DPs	3
1.3 Regulatory requirements	4
1.4 Sources of impurities	6
1.5 Benefits of isolation and characterization of impurities and DPs	8
1.6 Identification and Structure Elucidation of Impurities and DPs	9
1.7 Stability Indicating Assay Method (SIAMs)	15
1.8 QbD (Quality by Design) and DoE (Design of Experiments)	19
1.9 References	22
<b>CHAPTER 2: AIMS AND OBJECTIVES</b>	29
<b>CHAPTER 3: IMPURITY PROFILING AND DEGRADATION STUDY OF PIDOTIMOD</b>	30-153
3.1. SELECTION OF DRUG	30
3.2 DRUG PROFILE	31
3.3 LITERATURE REVIEW	32
3.4. SECTION –A DEVELOPMENT AND VALIDATION OF QbD BASED STABILITY INDICATING HPLC METHOD	32-82
3.4.1 EXPERIMENTAL	32
3.4.2 RESULTS AND DISCUSSION	39
3.4.2.1 Determination of suitable wavelength	39
3.4.2.2 Method optimization and development	40
3.4.2.3 Method Validation using ICH Q2(R1) guideline and total error approach	62
3.4.2.4 Uncertainty of Measurement	72
3.4.2.5 Stress Degradation studies	72
3.4.2.6 Applicability of developed stability indicating assay method for analysis of formulation (Synthetic mixture)	82
3.5. SECTION –B DEGRADATION KINETIC STUDY OF PIDOTIMOD BY HPLC	82-94

<b>METHOD</b>	
3.5.1 EXPERIMENTAL	82
3.5.2 RESULTS AND DISCUSSION	83
3.5.2.1 Kinetics of acid, base and oxidative degradation	83
3.5.2.2 Kinetics of neutral and photolytic degradation	91
<b>3.6 SECTION-C</b>	<b>94-114</b>
<b>ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF PIDOTIMOD</b>	
3.6.1 EXPERIMENTAL	94
3.6.2 RESULTS AND DISCUSSION	98
3.6.2.1 Isolation and Purification of DPs	98
3.6.2.2 Structural characterization of DPs	101
<b>3.7 SECTION-D</b>	<b>114-131</b>
<b>IMPURITY PROFILING AND DEGRADATION STUDY OF PIDOTIMOD</b>	
3.7.1 EXPERIMENTAL	114
3.7.2 RESULTS AND DISCUSSION	115
3.7.2.1 LC-PDA Study	116
3.7.2.2 LC-MS/MS study and characterization of DPs	116
<b>3.8 SECTION-E</b>	<b>131-149</b>
<b>CHIRAL SEPARATION OF PIDOTIMOD, ISOLATED DEGRADATION PRODUCT-2 AND DEVELOPMENT OF STABILITY INDICATING CHIRAL RP-HPLC ASSAY METHOD</b>	
3.8.1 EXPERIMENTAL	131
3.8.2 RESULTS AND DISCUSSION	134
3.8.2.1 Selection and Optimization of suitable chromatographic condition	134
3.8.2.2 Method Validation	137
3.8.2.3 Applicability of the developed SIAM method	141
3.8.2.4 Stress Degradation Study	142
3.8.2.5 LC-MS/MS study of PDM, DP-2 and their enantiomers	146
<b>3.9 CONCLUSION</b>	<b>149</b>
<b>3.10 REFERENCES</b>	<b>150-153</b>
<b>CHAPTER 4: IMPURITY PROFILING AND DEGRADATION STUDY OF EDARAVONE</b>	<b>154-292</b>

4.1. SELECTION OF DRUG	154
4.2 DRUG PROFILE	155
4.3 LITERATURE REVIEW	156
4.4 SECTION –A DEVELOPMENT AND VALIDATION OF QbD BASED STABILITY INDICATING HPLC METHOD	156-199
4.4.1 EXPERIMENTAL	156
4.4.2 RESULTS AND DISCUSSION	160
4.4.2.1 Determination of suitable wavelength	160
4.4.2.2 Method optimization and development by QbD approach	161
4.4.2.3 Method Validation using ICH Q2(R1) guideline	191
4.4.2.4 Stress Degradation studies	196
4.4.2.5 Applicability of developed stability indicating assay method for analysis formulation	199
4.5 SECTION-B DEGRADATION KINETIC STUDY OF EDARAVONE BY HPLC METHOD	200-209
4.5.1 EXPERIMENTAL	200
4.5.2 RESULTS AND DISCUSSION	201
4.5.2.1 Kinetics of acid and base Degradation	201
4.5.2.2 Kinetics of Neutral, Oxidative and Photolytic Degradation	206
4.6 SECTION –C DEVELOPMENT AND VALIDATION OF QbD BASED STABILITY INDICATING HPTLC METHOD	209-232
4.6.1 EXPERIMENTAL	209
4.6.2 RESULTS AND DISCUSSION	211
4.6.2.1 Method development and optimization by QbD approach	211
4.6.2.2 Method validation	226
4.6.2.3 Stress Degradation Study	230
4.6.2.4 Application of developed HPTLC method	232
4.7 SECTION-D DEGRADATION KINETIC STUDY OF EDARAVONE BY HPTLC METHOD	232-241
4.7.1 EXPERIMENTAL	232
4.7.2 RESULTS AND DISCUSSION	233

4.7.2.1 Kinetics of acid and base Degradation	233
4.7.2.2 Kinetics of Neutral, Oxidative and Photolytic Degradation	238
<b>4.8 SECTION-E</b> <b>ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF EDARAVONE</b>	241-268
4.8.1 EXPERIMENTAL	241
4.8.2 RESULTS AND DISCUSSION	247
4.8.2.1 Isolation and Purification of DPs	247
4.8.2.2 Structural characterization of DPs	249
<b>4.9 SECTION-F</b> <b>IMPURITY PROFILING AND DEGRADATION STUDY OF EDARAVONE</b>	268-289
4.9.1 EXPERIMENTAL	268
4.9.2 RESULTS AND DISCUSSION	269
4.9.2.1 LC-PDA Study	270
4.9.2.2 LC-MS/MS study and characterization of DPs	271
4.10 CONCLUSION	289
4.11 REFERENCES	290-292
<b>CHAPTER 5: IMPURITY PROFILING AND DEGRADATION STUDY OF CICLOPIROX OLAMINE</b>	293-350
5.1 SELECTION OF DRUG	293
5.2 DRUG PROFILE	294
5.3 LITERATURE REVIEW	295
<b>5.4. SECTION –A</b> <b>DEVELOPMENT AND VALIDATION OF QbD BASED STABILITY INDICATING RP-HPLC METHOD</b>	297-332
5.4.1 EXPERIMENTAL	297
5.4.2 RESULTS AND DISCUSSION	302
5.4.2.1 Determination of suitable wavelength	302
5.4.2.2 Method optimization and development	303
5.4.2.3 Method Validation using ICH Q2(R1) guideline and total error approach	320
5.4.2.4 Uncertainty of Measurement	329
5.4.2.5 Stress Degradation studies	330
5.4.2.6 Applicability of developed stability indicating assay method	

for analysis of formulation	332
5.5 SECTION –B DEGRADATION KINETIC STUDY OF CICLOPIROX OLAMINE BY HPLC METHOD	333-337
5.5.1 EXPERIMENTAL	333
5.5.2 RESULTS AND DISCUSSION	334
5.5.2.1 Kinetics of oxidative degradation	334
5.5.2.2 Kinetics of photolytic degradation	336
5.6 SECTION-C IMPURITY PROFILING AND DEGRADATION STUDY OF CICLOPIROX OLAMINE	337-347
5.6.1 EXPERIMENTAL	337
5.6.2 RESULTS AND DISCUSSION	338
5.6.2.1 LC-PDA Study	339
5.6.2.2 LC-MS/MS study and characterization of DPs	340
5.7 CONCLUSION	348
5.8 REFERENCES	348-350
<b>CHAPTER 6: SUMMARY AND CONCLUSION</b>	351-357
<b>LIST OF PUBLICATIONS</b>	358